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Genetic correlations and genome-wide
associations of cortical structure in general
population samples of 22,824 adults
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Cortical thickness, surface area and volumes vary with age and cognitive function, and in
neurological and psychiatric diseases. Here we report heritability, genetic correlations and
genome-wide associations of these cortical measures across the whole cortex, and in 34
anatomically predefined regions. Our discovery sample comprises 22,824 individuals from 20
cohorts within the Cohorts for Heart and Aging Research in Genomic Epidemiology
(CHARGE) consortium and the UK Biobank. We identify genetic heterogeneity between
cortical measures and brain regions, and 160 genome-wide significant associations pointing
to wnt/β-catenin, TGF-β and sonic hedgehog pathways. There is enrichment for genes
involved in anthropometric traits, hindbrain development, vascular and neurodegenerative
disease and psychiatric conditions. These data are a rich resource for studies of the biological
mechanisms behind cortical development and aging.
https://doi.org/10.1038/s41467-020-18367-y OPEN
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The cortex is the largest part of the human brain, associatedwith higher brain functions, such as perception, thought,and action. Brain cortical thickness (CTh), cortical surface
area (CSA), and cortical volume (CV) are morphological markers
of cortical structure obtained from magnetic resonance imaging
(MRI). These measures change with age1–3 and are linked to
cognitive functioning4,5. The human cortex is also vulnerable to a
wide range of disease or pathologies, ranging from developmental
disorders and early onset psychiatric and neurological diseases to
neurodegenerative conditions manifesting late in life. Abnorm-
alities in global or regional CTh, CSA, and CV have been
observed in neurological and psychiatric disorders, such as Alz-
heimer’s disease6, Parkinson’s disease7, multiple sclerosis8, schi-
zophrenia9, bipolar disorder9, depression10, and autism11. The
best method to study human cortical structure during life is using
brain MRI. Hence, understanding the genetic determinants of the
most robust MRI cortical markers in apparently normal adults
could identify biological pathways relevant to brain development,
aging, and various diseases. Neurons in the neocortex are orga-
nized in columns which run perpendicular to the surface of the
cerebral cortex12; and, according to the radial unit hypothesis,
CTh is determined by the number of cells within the columns and
CSA is determined by the number of columns13.
Thus, CTh and CSA reflect different mechanisms in cortical
development13,14 and are likely influenced by different genetic
factors15–18. CV, which is the product of CTh and CSA, is
determined by a combination of these two measures, but the
relative contribution of CTh and CSA to CV may vary across
brain regions. CTh, CSA, and CV are all strongly heritable
traits15–21 with estimated heritability of 0.69–0.81 for global CTh,
and from 0.42 to 0.90 for global CSA15,16,18. Across different
cortical regions, however, there is substantial regional variation in
heritability of CTh, CSA, and CV15–21.
Since CTh, CSA, and CV are differentially heritable and
genetically heterogeneous, we explore the genetics of each of these
imaging markers using genome-wide association analyses
(GWAS) in large population-based samples. We study CTh, CSA,
and CV in the whole cortex and in 34 cortical regions in 22,824
individuals from 21 discovery cohorts and replicate the strongest
associations in 22,363 persons from the Enhancing Neuroimaging
Genetics through Meta-analysis (ENIGMA) consortium. Our
analyses reveal 160 genome-wide significant associations pointing
to wnt/β-catenin, TGF-β, and sonic hedgehog pathways. We
observe genetic heterogeneity between cortical measures and
brain regions and find enrichment for genes involved in
anthropometric traits, hindbrain development, vascular and
neurodegenerative disease, and psychiatric conditions.
Results
Genome-wide association analysis. The analyses of global CTh,
CSA, and CV included 22,163, 18,617, and 22,824 individuals,
respectively. After correction for multiple testing (pDiscovery <
1.09 × 10−9), we identified no significant associations with global
CTh. However, we identified 12 independent loci associated with
global CSA (n= 6) and CV (n= 6). These are displayed in
Supplementary Data 1 and Supplementary Figs. 1 and 2. Five of
the 6 CSA loci were replicated in an external (ENIGMA con-
sortium) sample22. The ENIGMA consortium only analyzed CSA
and CTh.
GWAS of CTh, CSA, and CV in 34 cortical regions of interest
(ROIs) identified 148 significant associations. There were 16
independent loci across 8 chromosomes determining CTh of 9
regions (Supplementary Data 2), 54 loci across 16 chromosomes
associated with CSA of 21 regions (Supplementary Data 3), and
78 loci across 17 chromosomes determining CV of 23 cortical
regions (Supplementary Data 4). We replicated 57 out of 64
regional CTh and CSA loci that were available in the ENIGMA
consortium sample22 using a conservative replication threshold of
pReplication= 3.1 × 10−4, 0.05/160. Region-specific variants with
the strongest association at each genomic locus are shown in
Tables 1–3. Chromosomal ideograms showing genome-wide
significant associations with global and regional cortical measures
in the discovery stage are presented in Fig. 1.
If we had used a more stringent threshold of pDiscovery < 4.76 ×
10−10= 5 × 10−8/105, correcting for all the 105 GWAS analyses
performed, we would have identified 142 significant associations
(Supplementary Data 1–4).
The strongest associations with CTh and CV were observed for
rs2033939 at 15q14 (pDiscovery, CTh= 1.17 × 10−73 and pDiscovery,
CV= 4.34 × 10−133) in the postcentral (primary somatosensory)
cortex, and for CSA with rs1080066 at 15q14 (pDiscovery, CSA=
8.45 × 10−109) in the precentral (primary motor) cortex. Figure 2
shows the lowest p-value of each cortical region. The postcentral
cortex was also the region with the largest number of independent
associations, mainly at a locus on 15q14. The corresponding
regional association plots are presented in Supplementary Fig. 3.
Quantile-quantile plots of all meta-analyses are presented in
Supplementary Figs. 4–7 and the corresponding genomic inflation
factors (λGC), LD score regression (LDSR) intercepts, and ratios
are shown in Supplementary Data 5. Although we observe inflated
test statistics for some traits with λGC between 1.02 and 1.11,
LDSR intercepts between 0.98 and 1.02 indicate that the inflation
is mainly due to polygenicity. For traits with λGC > 1.05, the LDSR
ratios range between 0.00 and 0.15 which means that a maximum
of 15% of the inflation is due to other causes.
Associations across cortical measures and with other traits.
Supplementary Data 6 presents variants that are associated with
the CSA or the CV across multiple regions. We observed 25 single
nucleotide polymorphisms (SNPs) that determined both the CSA
and CV of a given region, 4 SNPs that determined CTh and CV of
the same region, but no SNPs that determined both the CTh and
CSA of any given region (Supplementary Data 7). We also
checked the overlap between our findings and two previous
GWAS studies, including 842823 and 19,62124 individuals from
the UK Biobank, which among other phenotypes, investigate
CTh, CSA, and CV (Supplementary Data 8). Regarding CTh, one
variant, rs2033939 at 15q14, was associated with CTh of the
postcentral gyrus in both studies. For CSA and CV, we found 11
associations at 15q14, 14q23.1 and 3q24, and 14 associations at
15q14, 14q23.1, 3q24, 8q24.1, 12q14.3, and 20q13.2, respectively,
with the same cortical region as in our study. Out-of-sample
polygenic risk score (PRS) analyses showed associations (pPRS <
4.76 × 10−3) with all investigated cortical measures in all cortical
regions in 7800 UK Biobank individuals (Supplementary Data 9).
For CTh, we observed the maximum phenotypic variance
explained by the PRS (RPRS2) in the global cortex (RPRS2= 0.015,
pPRS= 1.05 × 10−26), and for CSA and CV in the pericalcarine
cortex (RPRS2,CSA= 0.029, pPRS,CSA= 1.29 × 10−50; RPRS2,CV=
0.032, pPRS,CV= 5.30 × 10−56). When assessing genetic overlap
with other traits, we observed that SNPs determining these cor-
tical measures have been previously associated with anthropo-
metric (height), neurologic (Parkinson’s disease, corticobasal
degeneration, and Alzheimer’s disease), psychiatric (neuroticism
and schizophrenia) and cognitive performance traits as well as
with total intracranial volume (TIV) on brain MRI (Supple-
mentary Data 10–12).
Gene identification. Positional mapping based on ANNOVAR
showed that most of the lead SNPs were intergenic and intronic
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(Fig. 3). One variant, rs2279829, which was associated with both
CSA and CV of the pars triangularis, postcentral and supra-
marginal cortices, is located in the 3′UTR of ZIC4 at 3q24. We
also found an exonic variant, rs10283100, in gene ENPP2 at
8q24.12 associated with CV of the insula.
We used multiple strategies beyond positional annotation to
identify specific genes implicated by the various GWAS associated
SNPs. FUMA identified 232 genes whose expression was
determined by these variants (eQTL) and these and other genes
implicated by chromatin interaction mapping are shown in
Supplementary Data 13–15. MAGMA gene-based association
analyses revealed 70 significantly associated (p < 5.87 × 10−8)
genes (Supplementary Data 16–18). For global CSA and CV, 7 of
9 genes associated with each measure overlapped, but there was
no overlap with global CTh. For regional CSA and CV, we found
28 genes across 13 cortical regions that determined both measures
in the same region. Figure 4 summarizes the results of GTEx
eQTL, chromatin interaction, positional annotation, and gene-
based mapping strategies for all regions. While there are
overlapping genes identified using different approaches, only
DAAM1 gene (Chr14q23.1) is identified by all types of gene
mapping for CV of insula. eQTL associations of our independent
lead SNPs in the Religious Orders Study Memory and Aging
Project (ROSMAP) dorsolateral frontal cortex gene expression
dataset are presented in Supplementary Data 19.
Pathway analysis. MAGMA gene set analyses identified 7 path-
ways for CTh, 3 pathways for CSA and 9 pathways for CV
(Supplementary Data 20). Among them are the gene ontology
(GO) gene sets hindbrain morphogenesis (strongest association
with thickness of middle temporal cortex), forebrain generation
of neurons (with surface area of precentral cortex), and central
nervous system neuron development (with volume of transverse
temporal cortex). However, after Bonferroni correction only one
significant pathway (p < 1.02 × 10−7) remained: regulation of
catabolic process for CTh of the inferior temporal cortex. Inna-
teDB pathway analyses of genes mapped to independent lead
SNPs by FUMA showed a significant overlap between CTh and
CSA genes and the Wnt signaling pathway (Supplementary
Figs. 8 and 9) as well as a significant overlap between CV genes
and the basal cell carcinoma pathway (Supplementary Fig. 10).
Heritability. Heritability estimates (h2) of global CTh were 0.64
(standard error (se)= 0.12; pSOLAR= 3 × 10−7) in the ASPS-Fam
study and 0.45 (se= 0.08; pGCTA= 2.5 × 10−7) in the Rotterdam
study (RS). For CSA, h2 was 0.84 (se= 0.12; pSOLAR= 2.63 × 10−11)
in ASPS-Fam and 0.33 (se= 0.08, pGCTA= 1 × 10−4) in RS, and for
CV, h2 was 0.80 (se= 0.11; pSOLAR= 1.10 × 10−9) in ASPS-Fam
and 0.32 (se= 0.08; pGCTA= 1 × 10−4) in RS. There was a large
range in heritability estimates of regional CTh, CSA, and CV
(Supplementary Data 21).
Heritability based on common SNPs as estimated with LDSR
was 0.25 (se= 0.03) for global CTh, 0.29 (se= 0.04) for global
CSA and 0.30 (se= 0.03) for global CV. LDSR heritability
estimates of regional CTh, CSA, and CV are presented in
Supplementary Data 21 and Supplementary Fig. 11. For the
regional analyses, the estimated heritability ranged from 0.05 to
0.18 for CTh, from 0.07 to 0.36 for CSA and from 0.06 to 0.32 for
CV. Superior temporal cortex (h2CTh= 0.18, h2CSA= 0.30, h2CV
= 0.26), precuneus (h2CTh= 0.16, h2CSA= 0.29, h2CV= 0.28) and
pericalcarine (h2CTh= 0.15, h2CSA= 0.36, h2CV= 0.32) are
among the most genetically determined regions.
The results of partitioned heritability analyses for global and
regional CTh, CSA, and CV with functional annotation and
additionally with cell-type-specific annotation are presented inT
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Table 3 Genome-wide significant associations (pDiscovery < 1.09 × 10−9) of global and regional CV.
Lobe Region Locus Position Lead SNP Nearest gene Annotation N pDiscovery
Global 6q22.32 126792095 rs11759026 MIR588 Intergenic 22,410 6.31E−19
17q21.31 44790203 rs169201 NSF Intronic 22,784 2.11E−13
17q21.32 43549608 rs149366495 PLEKHM1 Intronic 22,099 8.18E−13
12q14.3 66358347 rs1042725 HMGA2 3’UTR 22,784 7.04E−11
12q23.2 102921296 rs11111293 IGF1 Intergenic 22,784 5.45E−10
6q22 109002042 rs4945816 FOXO3 3’UTR 22,784 8.93E−10
Frontal Superior frontal 5q14.3 92186429 rs888814 NR2F1-AS1 Intergenic 22,692 3.29E−13
Rostral middle frontal 15q14 39636227 rs17694988 C15orf54 Intergenic 22,793 3.15E−11
Caudal middle frontal 2q12.1 105460333 rs745249 LINC01158 ncRNA_intronic 22,726 2.35E−11
6q22.32 127068983 rs853974 RSPO3 Intergenic 22,351 4.82E−11
Pars opercularis 5q23.3 128734008 rs12187568 ADAMTS19 Intergenic 20,753 4.27E−18
15q14 39639898 rs4924345 C15orf54 Intergenic 22,758 1.97E−14
Pars triangularis 3q24 147106319 rs2279829 ZIC4 UTR3 22,759 3.16E−23
7q21.3 96196906 rs67055449 LOC100506136 Intergenic 22,759 4.03E−19
15q14 39633904 rs2033939 C15orf54 Intergenic 22,759 8.49E−14
7q21.3 96129071 rs62470042 C7orf76 Intronic 22,759 7.38E−13
6q15 91942761 rs12660096 MAP3K7 Intergenic 22,759 4.74E−10
Lateral orbitofrontal 14q22.2 54769839 rs6572946 CDKN3 Intergenic 22,801 2.29E−10
Precentral 15q14 39634222 rs1080066 C15orf54 Intergenic 22,699 5.84E−125
10q25.3 118648841 rs3781566 SHTN1 Intronic 22,699 4.68E−11
Temporal Superior temporal 3q26.32 177296448 rs13084960 LINC00578 ncRNA_intronic 22,681 1.12E−11
Banksts 14q23.1 59072226 rs186347 KIAA0586 Intergenic 22,727 1.15E−15
Fusiform 14q23.1 59833172 rs1547199 DAAM1 Intronic 22,605 4.58E−10
1p33 47980916 rs6658111 FOXD2 Intergenic 22,605 7.78E−10
Transverse temporal 2q23.2 150012936 rs2046268 LYPD6B Intronic 22,786 2.55E−12
Parahippocampal 2q33.1 199809716 rs966744 SATB2 Intergenic 22,747 2.23E−10
Parietal Superior parietal 15q14 39633904 rs2033939 C15orf54 Intergenic 22,723 4.28E−23
16q24.2 87225139 rs4843227 LOC101928708 Intergenic 22,723 1.16E−13
19p13.2 13109763 rs68175985 NFIX Intronic 21,777 3.27E−11
5q15 92866553 rs62369942 NR2F1-AS1 ncRNA_intronic 21,664 4.32E−10
Inferior parietal 20q13.2 52448936 rs6097618 SUMO1P1 Intergenic 22,701 2.09E−17
12q14.3 65797096 rs2336713 MSRB3 Intronic 22,701 2.47E−13
3q13.11 104724634 rs971551 ALCAM Intergenic 22,701 2.34E−10
Supramarginal 15q14 39632013 rs71471500 THBS1 Intergenic 22,645 9.71E−28
14q23.1 59627631 rs2164950 DAAM1 Intergenic 22,645 3.59E−20
3q24 147106319 rs2279829 ZIC4 UTR3 22,645 5.36E−18
Postcentral 15q14 39633904 rs2033939 THBS1 Intergenic 22,662 4.34E−133
3q24 147106319 rs2279829 ZIC4 UTR3 22,662 2.54E−17
9q21.13 76144318 rs67286026 ANXA1 Intergenic 22,662 5.03E−11
2q36.3 226563259 rs16866701 NYAP2 Intergenic 22,545 5.69E−11
Precuneus 14q23.1 59628609 rs74826997 DAAM1 Intergenic 22,803 4.85E−20
3q28 190663557 rs35055419 OSTN Intergenic 22,428 2.02E−10
2p22.2 37818236 rs2215605 CDC42EP3 Intergenic 22,803 3.43E−10
3q13.11 104713881 rs12495603 ALCAM Intergenic 22,803 9.71E−10
Occipital Lateral occipital 14q23.1 59627631 rs2164950 DAAM1 Intergenic 22,799 6.89E−16
Lingual 14q23.1 59625997 rs73313052 DAAM1 Intergenic 22,805 1.06E−20
6q22.32 127089401 rs2223739 RSPO3 Intergenic 22,805 1.75E−10
Cuneus 14q23.1 59625997 rs73313052 DAAM1 Intergenic 22,799 4.59E−43
11p15.3 12072213 rs11022131 DKK3 Intergenic 22,799 5.96E−12
13q31.1 80192236 rs9545156 LINC01068 Intergenic 22,799 4.09E−10
Pericalcarine 14q23.1 59628679 rs76341705 DAAM1 Intergenic 22,824 1.39E−29
13q31.1 80191873 rs9545155 LINC01068 intergenic 22,824 2.25E−13
11p14.1 30876113 rs273594 DCDC5 Intergenic 22,824 3.51E−13
1p13.2 113208039 rs12046466 CAPZA1 Intronic 22,824 2.36E−12
1p33 47980916 rs6658111 FOXD2 Intergenic 22,824 3.85E−11
11q22.3 104012656 rs1681464 PDGFD Intronic 22,824 7.51E−11
6q22.32 127096181 rs9401907 RSPO3 Intergenic 22,824 2.11E−10
7p21.1 18904400 rs12700001 HDAC9 Intronic 22,824 2.12E−10
5q12.1 60315823 rs10939879 NDUFAF2 Intronic 22,824 2.92E−10
Caudal anterior cingulate 5q14.3 82852578 rs309588 VCAN Intronic 22,748 2.60E−10
Insula 11q23.1 110949402 rs321403 C11orf53 Intergenic 22,543 9.58E−12
8q24.12 120596023 rs10283100 ENPP2 Exonic 21,481 8.29E−11
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Supplementary Data 22 and 23. For global CTh, we found
enrichment for super-enhancers, introns and histone marks.
Repressors and histone marks were enriched for global CSA, and
introns, super-enhancers, and repressors for global CV. For
regional CSA and CV the highest enrichment scores (>18) were
observed for conserved regions.
Genetic correlation. We found high genetic correlation (rg)
between global CSA, and global CV (rg= 0.81, pLDSR= 1.2 × 10−186)
and between global CTh and global CV (rg= 0.46, pLDSR= 1.4 ×
10−14), but not between global CTh and global CSA (rg=−0.02,
pLDSR= 0.82). Whereas the genetic correlation between CSA and CV
was strong (rg > 0.7) in most of the regions (Supplementary Data 24
and Supplementary Fig. 12), it was generally weak between CSA and
CTh with rg < 0.3, and ranged from 0.09 to 0.69 between CTh and
CV. The postcentral and lingual cortices were the two regions with
the highest genetic correlations between both CTh and CV, as well as
CTh and CSA.
Genetic correlation across the various brain regions for CTh
(Supplementary Fig. 13, Supplementary Data 25), CSA (Supple-
mentary Fig. 14, Supplementary Data 26), and CV
(Supplementary Fig. 15, Supplementary Data 27) showed a
greater number of correlated regions for CTh and greater inter-
regional variation for CSA and CV. Supplementary Data 28–30
and Supplementary Figs. 16–18 show genome-wide genetic
correlations between the cortical measures and anthropometric,
neurological and psychiatric, and cerebral structural traits.
Discussion
In our genome-wide association study of up to 22,824 individuals
for MRI determined cortical measures of global and regional
thickness, surface area, and volume, we identified 160 genome-
wide significant associations across 19 chromosomes. Heritability
was generally higher for cortical surface area and volume than for
thickness, suggesting a greater susceptibility of cortical thickness
to environmental influences. We observed strong genetic corre-
lations between surface area and volume, but weak genetic cor-
relation between surface area and thickness. We identified the
largest number of novel genetic associations with cortical
volumes, perhaps due to our larger sample size for this pheno-
type, which was assessed in all 21 discovery samples.
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Fig. 1 Chromosomal ideogram of genome-wide significant associations with measures of cortical structure. Cortical surface areas, cortical volumes
and cortical thickness. Each point represents the significantly associated variant, the colors correspond to the different cortical regions and the shape to
different type of measument (pDiscovery < 1.09 × 10−9).
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It is beyond the scope of our study to discuss each of the 160
associations identified. A large number of the corresponding
genes are involved in pathways that regulate morphogenesis of
neurons, neuronal cell differentiation, and cell growth, as well as
cell migration and organogenesis during embryonic development.
At a molecular level, the wnt/β-catenin, TGF-β, and sonic
hedgehog pathways are strongly implicated. Gene-set-enrichment
analyses revealed biological processes related to brain morphol-
ogy and neuronal development.
Broad patterns emerged showing that genes determining cor-
tical structure are also often implicated in development of the
cerebellum and brainstem (KIAA0586, ZIC4, ENPP2) as well as
the neural tube (one carbon metabolism genes DHFR and
MSRBB3, the latter also associated with hippocampal volumes25).
These genes determine development of not only neurons but also
astroglia (THBS1) and microglia (SALL1). They determine sus-
ceptibility or resistance to a range of insults: inflammatory, vas-
cular (THBS1, ANXA1, ARRDC3-AS126) and neurodegenerative
(C15orf53, ZIC4, ANXA1), and have been associated with
pediatric and adult psychiatric conditions (THBS1).
There is a wealth of information in the supplementary
tables that can be mined for a better understanding of brain
development, connectivity, function and pathology. We highlight
this potential by discussing in additional detail, the possible
0
c
b
a
5 10 15
–log10(p-value)
20 25 > 30
Fig. 2 Lowest discovery meta-analysis p-value of CSA, CTh, and CV in each cortical region. a Lowest pDiscovery of CSA, b lowest pDiscovery of CTh, c lowest
pDiscovery of CV.
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significance of 6 illustrative loci, 5 of which, at 15q14, 14q23.1,
6q22.32, 17q21.31, and 3q24, associate with multiple brain
regions at low p-values, while the locus at 8q24.12 identifies a
plausible exonic variant.
The Chr15q14 locus was associated with cortical thickness,
surface area, and volumes in the postcentral gyrus as well as with
surface area or volume across six other regions in the frontal and
parietal lobes. Lead SNPs at this locus were either intergenic
between C15orf53 and C15orf54, or intergenic between C15orf54
and THBS1 (Thrombospondin-1). C15orf53 has been associated
with an autosomal recessive form of spastic paraplegia showing
intellectual disability and thinning of the corpus callosum (her-
editary spastic paraparesis 11, or Nakamura Osame syndrome).
Variants of THBS1 were reported to be related to autism27 and
schizophrenia28. The protein product of THBS1 is involved in
astrocyte induced synaptogenesis29, and regulates chain migra-
tion of interneuron precursors migrating in the postnatal radial
migration stream to the olfactory bulb30. Moreover, THBS1 is an
activator of TGFβ signaling, and an inhibitor of pro-angiogenic
nitric oxide signaling, which plays a role in several cancers and
immune-inflammatory conditions.
Variants at Chr14q23.1 were associated with cortical surface
area and volume of all regions in the occipital lobe, as well as with
thickness, surface area, and volume of the middle temporal
cortex, banks of the superior temporal sulcus, fusiform, supra-
marginal and precuneus regions, areas associated with dis-
crimination and recognition of language or visual form. These
variants are either intergenic between KIAA0586, the product of
which is a conserved centrosomal protein essential for ciliogen-
esis, sonic hedgehog signaling and intracellular organization, and
DACT1, the product of which is a target for SIRT1 and acts on the
wnt/β-catenin pathway. KIAA0586 has been associated with
Joubert syndrome, another condition associated with abnormal
cerebellar development. Other variants are intergenic between
DACT1 and DAAM1 or intronic in DAAM1. DAAM1 has been
associated with occipital lobe volume in a previous GWAS31.
Locus 6q22.32 contains various SNPs associated with cortical
surface area and volume globally, and also within some frontal,
temporal and occipital regions. The SNPs are intergenic between
RSPO3 and CENPW. RSPO3 and CENPW have been previously
associated with intracranial32,33 and occipital lobe volumes31.
RSPO3 is an activator of the canonical Wnt signaling pathway
and a regulator of angiogenesis.
Chr17q21.31 variants were associated with global cortical
surface area and volume and with regions in temporal lobe. These
variants are intronic in the genes PLEKHM1, CRHR1, NSF, and
WNT3. In previous GWAS analyses, these genes have been
associated with general cognitive function34 and neuroticism35.
CRHR1, NSF, and WNT3 were additionally associated with Par-
kinson’s disease36 and intracranial volume32,33,37. The NSF gene
also plays a role in Neuronal Intranuclear Inclusion Disease38 and
CRHR1 is involved in anxiety and depressive disorders39. This
chromosomal region also contains the MAPT gene, which plays a
role in Alzheimer’s disease, Parkinson’s disease, and fronto-
temporal dementia40,41.
The protein product of the gene ZIC4 is a C2H2 zinc finger
transcription factor that has an intraneuronal, non-synaptic
expression and auto-antibodies to this protein have been asso-
ciated with subacute sensory neuronopathy, limbic encephalitis,
and seizures in patients with breast, small cell lung or ovarian
cancers. ZIC4 null mice have abnormal development of the visual
pathway42 and heterozygous deletion of the gene has also been
associated with a congenital cerebellar (Dandy-Walker) mal-
formation43, thus implicating it widely in brain development as
well as in neurodegeneration. C2H2ZF transcription factors are
the most widely expressed transcription factors in eukaryotes and
show associations with responses to abiotic (environmental)
stressors. Another transcription factor, FOXC1, also associated
with Dandy-Walker syndrome has been previously shown to be
associated with risk of all types of ischemic stroke and with stroke
Total 6a b c
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Chromatin
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Genebased
Total 8 Total 26 Total 34
25
6
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Fig. 4 Number of overlapping genes between gene mapping methods. Number of overlapping genes between FUMA eQTL mapping, FUMA chromatin
interaction mapping, ANNOVAR chromosome positional mapping, and MAGMA gene-based analysis for all cortical regions combined for cortical surface
area (a), thickness (b) and volume (c).
Surface area
UTR3
Exonic
Intergenic
Intronic
NcRNA intronicthickness
Volume
Fig. 3 Functional annotation categories for global and regional CTh, CSA,
and CV. Proportion of functional annotation categories for global and
regional cortical thickness (blue), surface area (light green), and volume
(yellow) assigned by ANNOVAR.
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severity. Thus, ZIC4 might be a biological target worth pursuing
to ameliorate neurodegenerative disorders.
We found an exonic SNP within the gene ENPP2 (Autotaxin)
at 8q24.12 to be associated with insular cortical volume. This gene
is differentially expressed in the frontal cortex of Alzheimer
patients44 and in mouse models of Alzheimer disease, such as the
senescence-accelerated mouse prone 8 strain (SAMP8) mouse.
Autotaxin is a dual-function ectoenzyme, which is the primary
source of the signaling lipid, lysophosphatidic acid. Besides Alz-
heimer disease, changes in autotaxin/lysophosphatidic acid sig-
naling have also been shown in diverse brain-related conditions,
such as intractable pain, pruritus, glioblastoma, multiple sclerosis,
and schizophrenia. In the SAMP8 mouse, improvements in
cognition noted after administration of LW-AFC, a putative
Alzheimer remedy derived from the traditional Chinese medic-
inal prescription ‘Liuwei Dihuang’ decoction, are correlated with
restored expression of four genes in the hippocampus, one of
which is ENPP2.
Among the other genetic regions identified, many have been
linked to neurological and psychiatric disorders, cognitive func-
tioning, cortical development, and cerebral structure (detailed
listing in Supplementary Data 31).
Heritability estimates are, as expected, generally higher in the
family-based Austrian Stroke Prevention-Family study (ASPS-Fam)
than in the Rotterdam Study (RS) for CTh (average h2ASPS-Fam=
0.52; h2RS= 0.26), CSA (0.62 and 0.30) and CV (0.57 and 0.23).
This discrepancy is explained by the different heritability estimation
methods: pedigree-based heritability in ASPS-Fam versus herit-
ability based on common SNPs that are in LD with causal
variants45 in RS.
Average heritability over regions is also higher for surface area
and volume, than for thickness. The observed greater heritability
of CSA compared to CTh is consistent with the previously
articulated hypothesis, albeit based on much smaller numbers,
that CSA is developmentally determined to a greater extent with
smaller subsequent decline after young adulthood, whereas CTh
changes over the lifespan as aging, neurodegeneration and vas-
cular injuries accrue1,3. It is also interesting that brain regions
more susceptible to early amyloid deposition (e.g., superior
temporal cortex and precuneus) have a higher heritability.
We found no or weak genetic correlation between CTh and
CSA, globally and regionally, and no common lead SNPs, which
indicates that these two morphological measures are genetically
independent, a finding consistent with prior reports15,16. In
contrast, we found strong genetic correlation between CSA and
CV and identified common lead SNPs for CSA and CV globally,
and in 12 cortical regions. Similar findings have been reported in
a previous publication16. The genetic correlation between CTh
and CV ranged between 0.09 and 0.77, implying a common
genetic background in some regions (such as the primary sensory
postcentral and lingual cortices), but not in others. For CTh, we
observed genetic correlations between multiple regions within
each of the lobes, whereas for CSA and CV, we found genetic
correlations mainly between different regions of the occipital lobe.
Chen et al.46 have also reported strong genetic correlation for
CSA within the occipital lobe. There were also a few genetic
correlations observed for regions from different lobes, suggesting
similarities in cortical development transcended traditional lobar
boundaries.
A limitation of our study is the heterogeneity of the MR
phenotypes between cohorts due to different scanners, field
strengths, MR protocols and MRI analysis software. This het-
erogeneity as well as the different age ranges in the participating
cohorts may have caused different effects over the cohorts. We
nevertheless combined the data of the individual cohorts to
maximize the sample size as it has been done in previous
CHARGE GWAS analyses31–33. To account for the heterogeneity
we used a sample-size weighted meta-analysis that does not
provide overall effect estimates. This method has lower power to
detect associations compared to inverse-variance weighted meta-
analysis and we therefore may have found less associations.Our
inability to replicate 8 of the 76 genome-wide significant findings
for CTh and CSA could be caused by false-positive results but
may also be explained by insufficient power due to a too small
sample size. Moreover, our sample comprises of mainly European
ancestry, limiting the generalizability to other ethnicities.
Strengths of our study are the population-based design, the large
age range of our sample (20–100 years), use of three cortical
measures as phenotypes of cortical morphometry, and the repli-
cation of our CTh and CSA findings in a large and independent
cohort. In conclusion, we identified patterns of heritability and
genetic associations with various global and regional cortical
measures, as well as overlap of MRI cortical measures with
genetic traits and diseases that provide new insights into cortical
development, morphology, and possible mechanisms of disease
susceptibility.
Methods
Study population. The sample of this study consist of up to 22,824 participants
from 20 population-based cohort studies collaborating in the Cohorts of Heart and
Aging Research in Genomic Epidemiology (CHARGE) consortium and the UK
Biobank (UKBB). All the individuals were stroke- and dementia free, aged between
20 and 100 years, and of European ancestry, except for ARIC AA with African
ancestry. Supplementary Data 32 provides population characteristics of each cohort
and the Supplementary Methods provide a short description of each study. Each
study secured approval from institutional review boards or equivalent organiza-
tions, and all participants provided written informed consent. Our results were
replicated using summary GWAS findings of 22,635 individuals from the ENIGMA
consortium.
Genotyping and imputation. Genotyping was conducted using various commer-
cially available genotyping arrays across the study cohorts. Prior to imputation,
extensive quality control was performed in each cohort. Genotype data were
imputed to the 1000 Genomes reference panel (mainly phase 1, version 3) using
validated software. Details on genotyping, quality control and imputation can be
found in Supplementary Data 33.
Phenotype definition. This study investigated CTh, CSA, and CV globally in the
whole cortex and in 34 cortical regions. Global and regional CTh was defined as the
mean thickness of the left and the right hemisphere in millimeter (mm). Global
CSA was defined as the total surface area of the left and the right hemisphere in
mm2, while regional CSA was defined as the mean surface area of the left and the
right hemisphere in mm2. Global and regional CV was defined as the mean volume
of the left and the right hemisphere in mm3. The 34 cortical regions are listed in
the Supplementary Methods. High resolution brain magnetic resonance imaging
(MRI) data was obtained in each cohort using a range of MRI scanners, field
strengths and protocols. CTh, CSA, and CV were generated using the Freesurfer
software package47 in all cohorts except for FHSucd, where an in-house segmen-
tation method was used. MRI protocols of each cohort can be found in Supple-
mentary Data 35 and descriptive statistics of CTh, CSA, and CV can be found in
Supplementary Data 36–38.
Genome-wide association analysis. Based on a predefined analysis plan, each
study fitted linear regression models to determine the association between global
and regional CTh, CSA, and CV and allele dosages of SNPs. Additive genetic effects
were assumed and the models were adjusted for sex, age, age2, and if needed for
study site and for principal components to correct for population stratification.
Cohorts including related individuals calculated linear mixed models to account for
family structure. Details on association software and covariates for each cohort are
shown in Supplementary Data 33. Models investigating regional CTh, CSA, and
CV were additionally adjusted for global CTh, global CSA and global CV,
respectively. Quality control of the summary statistics shared by each cohort was
performed using EasyQC48. Genetic variants with a minor allele frequency (MAF)
<0.05, low imputation quality (R2 < 0.4), and which were available in less than
10,000 individuals were removed from the analyses. Details on quality control are
provided in the Supplementary Methods.
We then used METAL49 to perform meta-analyses using the z-scores method,
based on p-values, sample size, and direction of effect, with genomic control
correction. To estimate the number of independent tests for the p-value threshold
correction, we used a non-parametric permutation testing procedure50–53 in the
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combined Rotterdam Study cohort (N= 4442) and UK Biobank (N= 8213). First,
we generated a random independent variable, to insure that there is no true
relationship between brain measurements and this variable. Second, we ran linear
regression analyses between this variable and all brain measurements one-by-one
in each of the cohorts separately (104 regressions in total per cohort). Third, we
saved the minimum p-value obtained from those 104 regressions. Then, as
suggested in literature54, we repeated this procedure 10.000 times. Therefore, at the
end we had 10.000 minimum p-values per cohort. The minimum p-value
distribution follows a Beta distribution Beta(m,n), where m= 1 and n is the degree
of freedom, which represents the number of independent tests in case of
permutation testing. Using python statistical library we fitted the Beta function
with the saved minimum p-values, and found n for Rotterdam Study and UK
Biobank identically equal to 46. Based on the permutation test results, the genome-
wide significance threshold was set a priori at 1.09 × 10−9 (=5 × 10−8/46). We used
the clumping function in PLINK55 (linkage disequilibrium (LD) threshold: 0.2,
distance: 300 kb) to identify the most significant SNP in each LD block. We used
LDSR to calculate genomic inflation factors (λGC), LDSR intercepts and LDSR
ratios for each meta-analysis. The LDSR intercept was estimated to differentiate
between inflation due to a polygenic signal and inflation due to population
stratification56. The LDSR ratio represents the amount of inflation that is due to
other causes than polygenicity such as population stratification or cryptic
relatedness.
For replication of our genome-wide significant CTh and CSA associations, we
used GWAS meta-analysis results from the ENIGMA consortium22 for all SNPs
that were associated at a p-value <5 × 10−8 and performed a pooled meta-analysis.
The p-value threshold for replication was set to 3.1 × 10−4 (=0.05/160: nominal
significance threshold divided by total number of lead SNPs). CV was not available
in the ENIGMA results. PRS analysis was performed for 7800 out of sample
subjects (not included in the current GWAS) from UK Biobank cohort using the
PRSice-2 software57 with standard settings. The significance threshold for the
association between the PRS and the phenotype was set to 4.76 × 10−3 (=0.05/105:
nominal significance divided by number GWAS phenotypes). The NHGRI-EBI
Catalog of published GWAS58 was searched for previous SNP-trait associations at a
p-value of 5 × 10−8 of lead SNPs. Regional association plots were generated with
LocusZoom59, and the chromosomal ideogram with PHENOGRAM (http://
visualization.ritchielab.org/phenograms/plot).
Annotation of genome-wide significant variants was performed using the
ANNOVAR software package60 and the FUMA web application61. FUMA eQTL
mapping uses information from three data repositories (GTEx, Blood eQTL
browser, and BIOS QTL browser) and maps SNPs to genes based on a significant
eQTL association. We used a false discovery rate threshold (FDR) of 0.05 divided
by number of tests (46) to define significant eQTL associations. Gene-based
analyses, to combine the effects of SNPs assigned to a gene, and gene set analyses,
to find out if genes assigned to significant SNPs were involved in biological
pathways, were performed using MAGMA62 as implemented in FUMA. The
significance threshold was set to 5.87 × 10−8 (=0.05/18522*46: FDR threshold
divided by number of genes and independent tests) for gene-based analyses and to
1.02 × 10−7 (=0.05/10651: FDR threshold divided by the number of gene sets) for
the gene set analyses. Additionally, FUMA was used to investigate a significant
chromatin interaction between a genomic region in a risk locus and promoter
regions of genes (250 bp upstream and 500 bp downstream of a TSS). We used an
FDR of 1 × 10−6 to define significant interactions.
We investigated cis (<1Mb) and trans (>1MB or on a different chromosome)
expression quantitative trait loci (eQTL) for genome-wide significant SNPs in 724
post-mortem brains from ROSMAP63,64 stored in the AMP-AD database. The
samples were collected from the gray matter of the dorsolateral prefrontal cortex.
The significance threshold was set to 0.001 (=0.05/46: FDR threshold divided by
the number of independent tests). For additional pathway analyses of genes that
were mapped to independent lead SNPs by FUMA, we searched the InnateDB
database65. The STRING database66 was used for visualizing protein–protein
interactions. Only those protein subnetworks with five or more nodes are shown.
Heritability. Additive genetic heritability (h2) of CTh, CSA, and CV was estimated
in two studies: the Austrian Stroke Prevention Family Study (ASPS-Fam; n= 365)
and the Rotterdam Study (RS, n= 4472). In the population-based family study
ASPS-Fam, the ratio of the genotypic variance to the phenotypic variance was
calculated using variance components models in SOLAR67. In case of non-nor-
malty, phenotype data were inverse-normal transformed. In RS, SNP-based her-
itability was computed with GCTA68. These heritability analyses were adjusted for
age and sex.
Heritability and partitioned heritability based on GWAS summary statistics was
calculated from GWAS summary statistics using LDSR) implemented in the LDSC
tool (https://github.com/bulik/ldsc). Partitioned heritability analysis splits genome-
wide SNP heritability into 53 functional annotation classes (e.g., coding, 3′UTR,
promoter, transcription factor binding sites, conserved regions etc.) and
additionally to 10 cell-type specific classes (e.g., central nervous system,
cardiovascular, liver, skeletal muscle, etc.) as defined by Finucane et al.69 to
estimate their contributions to heritability. The significance threshold was set to
2.05 × 10−5 (=0.05/53*46: nominal significance divided by number of functional
annotation classes and number of independent tests) for heritability partitioned on
functional annotation classes and 2.05 < 10−6 (=0.05/53*10*46: nominal
significance divided by number of functional annotation classes, number of cell
types and number of independent tests) for heritability partitioned on annotation
classes and cell types.
Genetic correlation. LDSR genetic correlation70 between CTh, CSA, and CV was
estimated globally and within each cortical region. The significance threshold was
set to 7.35 × 10−4 (nominal threshold (0.05) divided by number of regions (34) and
by number of correlations (CSA and CV, CSA and CTh). Genetic correlation was
also estimated between all 34 cortical regions for CTh, CSA, and CV, with the
significance threshold set to 8.91 × 10−5 (nominal threshold (0.05) divided by
number of regions (34) times the number of regions −1 (33) divided by 2 (half of
the matrix). Additionally, the amount of genetic correlation was quantified between
CTh, CSA, and CV and physical traits (height, body mass index), neurological and
psychiatric diseases (e.g., Alzheimer’s disease, Parkinson’s disease), cognitive traits
and MRI volumes (p-value threshold (0.05/46/number of GWAS traits). As
recommended by the LDSC tool developers, only HapMap3 variants were included
in these analyses, as these tend to be well-imputed across cohorts.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The genome-wide summary statistics that support the findings of this study are available
via the CHARGE Summary Results portal at the NCBI dbGaP website https://www.
omicsdi.org/dataset/dbgap/phs000930 upon publication, or from the corresponding
authors R.S. and S.S. upon reasonable request. The summary statistics may be used for
all scientific purposes except for the study of potentially sensitive and potentially
stereotyping phenotypes such as intelligence and addiction, since this is proscribed by the
consent terms for the NHLBI cohorts. Individual level data or study-specific summary
results are only available through controlled access. Data for the Framingham Study are
available through dbGaP, where qualified researchers can apply for authorization to access
(https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000007.
v30.p11). Individual level data for the ARIC and CHS studies are also available through
dbGaP. Data of European and Australian cohorts are available upon request, in keeping
with data sharing guidelines in the EU General Data Protection Regulation. Data from UK
Biobank can be accessed at http://www.ukbiobank.ac.uk and for the ENIGMA consortium
from medlandse@gmail.com. Individual level data for VETSA is not available due to
consent restrictions.
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